

BioRN Lounge with Michael Platten, Chairman, Department of Neurology, University Hospital Mannheim; Head CCU Neuroimmunology and Brain Tumor Immunology, DKFZ

**“A novel target in brain tumor immunotherapy
- from bench to bedside and back”**

Brain Tumors are one of the biggest therapeutic challenges in oncology. In this presentation, the development of a novel targeted immunotherapeutic approach from preclinical conceptualization to forward and reverse translation will be illustrated.

March 26, 2019, 7pm

At the restaurant Urban Kitchen, Poststr. 36/5 in Heidelberg

Register by emailing to Sibylle Geilenberg: sg@biorn.org



Michael Platten, Chairman, Department of Neurology, University Hospital Mannheim; Head CCU Neuroimmunology and Brain Tumor Immunology, DKFZ.

Michael Platten is a Professor of Neurology and Chairman of the Department of Neurology at the University Hospital in Mannheim and Head of the Department of Neuroimmunology and Brain Tumor Immunology at the German Cancer Research Center. He is a steering committee member of the German Neurooncology Working Group (NOA) and serves as a faculty member of the German Cancer Consortium and on the Management Board of the Helmholtz Institute for Translational Oncology (HiTRON).

Michael has received his MD from the University of Bonn, Germany and his postdoctoral training at the Universities of Tübingen, Germany and Stanford University. Michael discovered novel pathways involved in immune regulation in gliomas and pioneered the development of novel therapeutic strategies for the immunotherapy of gliomas and other types of cancer and is currently conducting early multicenter trials testing these strategies. His main scientific focus includes glioma immunogenicity, immune suppression, heterogeneity and personalized treatment strategies. Michael has published more than 130 articles in peer-reviewed journals including Nature, Nature Medicine, Science, PNAS, JCI, NEJM, Lancet Oncology and JCO.